June 19, 2024 09:22 AM EDT

Samsung Bio and Baxter dial up manufacturing deal to $223M

Anna Brown

News Reporter

Baxter Healthcare will pay Samsung Biologics an extra $208 million to manufacture certain drug products until the end of 2034 in a revised manufacturing contract …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Samsung Bio and Baxter dial up manufacturing deal to $223M

Anna Brown

News Reporter

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Sam­sung Bio and Bax­ter di­al up man­u­fac­tur­ing deal to $223M

Anna Brown

News Reporter

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Samsung Bio and Baxter dial up manufacturing deal to $223M

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva